ALX ONCOLOGY HOLDINGS INC
Tremor tracks 4 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 2 insiders sold shares within a monthSince Aug 17, 2026+3.9
Trials
- ALXOALX Oncology Inc.14Calm
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
FinishedPhase 2/3127 patientsMain results: May 24, 2024 - ALXOALX Oncology Inc.14Calm
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Running, no new patientsPhase 2172 patientsMain results: Mar 3, 2025 - ALXOALX Oncology Inc.14Calm
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Running, no new patientsPhase 2189 patientsMain results: Mar 3, 2025 - ALXOALX Oncology Inc.4Calm
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Signing up patientsPhase 2120 patientsMain results: Dec 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
3 sales (3 not pre-planned) · 0 purchases
- Lettmann JasonCHIEF EXECUTIVE OFFICER · Aug 17, 2026Sold 2,230 sharesabout $4 thousand · not pre-planned
- Wong ShellySVP, FINANCE AND CAO · Aug 17, 2026Sold 573 sharesabout $1 thousand · not pre-planned
- Wong ShellySVP, FINANCE AND CAO · Jul 1, 2026Sold 1,404 sharesabout $3 thousand · not pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Signed a major agreementNews report (8-K)Oct 15, 2026
- Quarterly reportQuarterly report (10-Q)Aug 6, 2026
- Shared quarterly resultsNews report (8-K)Aug 6, 2026
- An executive or board member joined or left; Shared information with investors; Other newsNews report (8-K)Jun 30, 2026
- Signed a major agreement; Ended a major agreementNews report (8-K)Jun 26, 2026